Regulatory Compliance

Boston – September 29, 2026 -- Gryphon has released Gryphon ONE on the Genesys Cloud AppFoundry, a real-time compliance layer that lets enterprises recover 35%-45% of their contactable customer universe by preventing over-suppression in outbound dialing campaigns.

Gryphon ONE screens calls against TCPA, TSR and Do Not Call rules before dialing occurs

The integration evaluates automated outbound dialing against the Telephone Consumer Protection Act, the Telemarketing Sales Rule, Do Not Call registries and state-specific standards in real time. Enterprises using highly regulated data sets can now operationalize governance, risk and compliance directly within Genesys Cloud outbound workflows, removing manual handoffs between compliance teams and campaign launch.

Seattle and San Francisco – September 29, 2026 -- ITpipes, a pipe inspection software provider used by more than 300 utilities, municipalities, and CCTV contractors across North America, has secured a strategic growth investment from Luminate Capital Partners to accelerate development of its AI-driven defect-detection technology.

Aging sewer networks face a $69 billion annual funding gap

The American Society of Civil Engineers gave U.S. wastewater infrastructure a D+ rating in its 2025 Report Card, pointing to more than 1.87 million miles of collection system pipe and a roughly $69 billion annual capital investment shortfall. Utilities are being asked to inspect more pipe and justify every dollar of spending with the same crews and budgets they had a decade ago, raising demand for condition data that regulators and finance officers can trust.

Staten Island, N.Y. – September 29, 2026 -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has enrolled the first patient in its PATHFINDER clinical trial evaluating ibezapolstat in patients with multiply-recurrent Clostridioides difficile infection (rCDI), a condition affecting up to 40% of patients treated with vancomycin after multiple prior episodes.

Fully funded pilot trial targets approximately 20 patients with severe recurrence history

The Phase 2 PATHFINDER study is a multicenter, open-label, single-arm trial enrolling patients who have experienced at least three CDI episodes within the past 12 months. Participants receive ibezapolstat for 14 days, with assessments for Clinical Cure at Day 16, Sustained Clinical Cure at Day 42, and recurrence rates tracked through Week 24.

Chandler, Arizona – September 29, 2026 -- VIAVI Solutions Inc. (NASDAQ: VIAV) has launched the CyberFlood CF50, billed as the industry's smallest and lightest all-in-one platform for enterprise-scale application performance, security and AI inference testing at speeds up to 100G.

CF50 delivers TLS performance 1.75X faster than nearest competitor

The 1U appliance combines Layer 4-7 traffic generation, security assessment and AI inference testing while offering what VIAVI describes as the industry's lowest power consumption. It includes native support for Post-Quantum Cryptography (PQC), addressing enterprise migration toward quantum-resistant encryption standards.

Calgary – September 29, 2026 -- Providence Therapeutics Holdings, Inc. has formed its first Clinical Advisory Board to guide development of its therapeutic mRNA cancer vaccine programs, including a personalized vaccine for pediatric brain cancer and off-the-shelf precision therapies for solid tumors.

Chief Medical Officer Leon Rozen chairs new four-member advisory panel

Dr. Rozen leads the board, which brings in Ezra Cohen, MD; Melinda Merchant, MD, PhD; and John Powderly, MD, to steer clinical strategy for the company's cancer vaccine pipeline.

Tempus AI oncology chief joins board with immunotherapy track record

Ezra Cohen currently serves as Chief Medical Officer for Oncology at Tempus AI. He previously held roles as Professor of Medicine and Division Chief of Hematology/Oncology at the Moores Cancer Center, University of California, San Diego.

Toronto – September 29, 2026 -- Jaguar Uranium Corp. (NYSE American: JAGU) has secured Environmental Impact Assessment approval from Chubut Province's Ministry of Environment for the La Rosada prospect, unlocking exploration rights across 59,895.3 hectares in Argentina.

Approval covers a quarter of the entire Laguna Salada project

The permit authorizes exploration activities across six properties totaling 59,895.3 hectares -- approximately 25% of the 230,000-hectare Laguna Salada uranium-vanadium project, the largest single component of the district-scale portfolio to date.

La Rosada sits 45 kilometers from a prospect already cleared this year

The newly permitted zone lies 45 kilometers northeast of the Guanaco prospect, which received its own EIA approval on March 2, 2026, extending Jaguar's cleared exploration footprint within the same project area.

Fairfax, Va. – September 29, 2026 -- CGI Federal Inc. has launched an AI Agent Catalog developed with Amazon Web Services, offering thousands of curated agentic AI use cases to help U.S. federal agencies automate cyber defense, fraud detection, benefits processing and back-office operations.

Catalog targets scalable, enterprise-wide agentic AI deployment

The offering provides tooling to generate self-directed agents capable of navigating secure federal environments while meeting government security, governance and compliance requirements. CGI Federal says the goal is to move agencies beyond isolated pilot programs toward mission-specific agent deployment at scale.

Brown Deer, Wis. – September 29, 2026 -- The Massachusetts Department of Transportation (MassDOT) has deployed 14 mobile Wrong-Way Detection Trailers built by TAPCO, part of a statewide push to identify wrong-way driving risk at unsignalized highway ramps before crashes occur. Texas and Arkansas transportation departments have also adopted the mobile trailers since the product launched earlier this year.

Fatal wrong-way crashes nearly doubled nationally over the past decade

Fatal wrong-way crashes on U.S. divided highways rose from 278 a year in 2014 to 520 in 2023, according to the AAA Foundation for Traffic Safety. Over that decade, 4,164 fatal wrong-way crashes killed 5,730 people, with wrong-way fatalities climbing faster than the overall fatal-crash rate.

Austin, Texas – September 29, 2026 -- CyberRatings.org has published new Cloud Network Firewall (CNFW) test results showing security effectiveness among nine evaluated products ranging from 0% to 99.95%, with only four earning a Recommended rating.

Four vendors clear the bar with 99.7% or higher security effectiveness

Fortinet FortiGate Next-Generation Firewall, HPE Juniper Networking vSRX Next Generation Firewall, Palo Alto Networks VM-Series Next-Generation Firewall, and Versa Networks Next Generation Firewall each achieved 99.7% or higher in Security Effectiveness, earning Recommended ratings. Tests were conducted by NSS Labs, CyberRatings' official testing partner, using the Cloud Network Firewall Test Methodology v4.1.

Washington, D.C. – September 29, 2026 -- LUNGevity Foundation has committed $2 million to fund two three-year clinical research projects aimed at improving the diagnosis of indeterminate pulmonary nodules (IPNs), a condition affecting more than 1.5 million Americans annually after routine chest CT scans.

The funding, awarded through the 2026 RTFCCR/LUNGevity Early Detection Award in partnership with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), targets a diagnostic gap that currently forces many patients into unnecessary invasive procedures or prolonged uncertainty when non-invasive tools fail to determine whether a lung nodule is benign or malignant.